tiprankstipranks
Trending News
More News >
Alibaba Health Information Technology Ltd. (HK:0241)
:0241
Hong Kong Market

Alibaba Health Information Technology (0241) Stock Forecast & Price Target

Compare
17 Followers
See the Price Targets and Ratings of:

0241 Analyst Ratings

Hold
5Ratings
Hold
2 Buy
2 Hold
1 Sell
Based on 5 analysts giving stock ratings to
Alibaba
Health Information Technology
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0241 Stock 12 Month Forecast

Average Price Target

HK$5.81
▲(37.00%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Alibaba Health Information Technology in the last 3 months. The average price target is HK$5.81 with a high forecast of HK$8.50 and a low forecast of HK$3.40. The average price target represents a 37.00% change from the last price of HK$4.24.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"HK$1","3":"HK$3","5":"HK$5","7":"HK$7","9":"HK$9"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.500000002593776,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$8.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.808978799,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$5.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.40000000103751,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$3.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3,5,7,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Sep<br/>2024","9":"Dec<br/>2024","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,5.02923076943029,5.318461538860581,5.607692308290871,5.896923077721162,6.186153847151452,6.475384616581742,6.764615386012033,7.053846155442324,7.343076924872614,7.632307694302904,7.921538463733195,8.210769233163486,{"y":8.500000002593776,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,4.822229138384616,4.904458276769231,4.986687415153846,5.068916553538462,5.151145691923077,5.233374830307692,5.315603968692308,5.397833107076924,5.480062245461538,5.562291383846154,5.644520522230769,5.7267496606153845,{"y":5.808978799,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,4.636923077002885,4.533846154005771,4.430769231008656,4.3276923080115415,4.2246153850144275,4.1215384620173126,4.018461539020198,3.915384616023083,3.8123076930259687,3.709230770028854,3.6061538470317394,3.503076924034625,{"y":3.40000000103751,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.7,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.889,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.67,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$8.50Average Price TargetHK$5.81Lowest Price TargetHK$3.40
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
HK$8.5
Buy
100.47%
Upside
Reiterated
07/04/25
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (NASDAQ: HRMY) and Alibaba Health Information Technology (Other OTC: ALBHF)
Macquarie Analyst forecast on HK:0241
Ellie JiangMacquarie
Macquarie
HK$3.4
Sell
-19.81%
Downside
Reiterated
06/24/25
Alibaba Health Information Technology (ALBHF) Receives a Sell from Macquarie
J.P. Morgan Analyst forecast on HK:0241
Alex YaoJ.P. Morgan
J.P. Morgan
HK$6HK$5
Hold
17.92%
Upside
Reiterated
06/04/25
J.P. Morgan Keeps Their Hold Rating on Alibaba Health Information Technology (ALBHF)
Goldman Sachs Analyst forecast on HK:0241
Lincoln KongGoldman Sachs
Goldman Sachs
Hold
Reiterated
06/04/25
Alibaba Health Information Technology (ALBHF) Receives a Hold from Goldman Sachs
UOB Kay Hian Analyst forecast on HK:0241
Unknown AnalystUOB Kay Hian
Not Ranked
UOB Kay Hian
HK$7HK$6.2
Buy
46.23%
Upside
Reiterated
05/21/25
CLSA
HK$4.5HK$4.8
Buy
13.21%
Upside
Reiterated
11/15/24
Alibaba Health (241:HK) PT Raised to HK$4.80 at CLSACLSA analyst Wenting Yu raised the price target on Alibaba Health (241:HK) to HK$4.80 (from HK$4.50) while maintaining a Outperform (2) rating.
Morgan Stanley Analyst forecast on HK:0241
Sean Wu CFAMorgan Stanley
Morgan Stanley
HK$5
Buy
17.92%
Upside
Reiterated
11/15/24
Positive Revenue and Profit Growth Drive 24% Upside Potential for Alibaba Health Information Technology
Jefferies Analyst forecast on HK:0241
Unknown AnalystJefferies
Not Ranked
Jefferies
HK$6
Buy
41.51%
Upside
Reiterated
10/25/24
Bank of America Securities Analyst forecast on HK:0241
Miranda ZhuangBank of America Securities
Bank of America Securities
HK$4.5HK$4.6
Buy
8.49%
Upside
Reiterated
10/16/24
Alibaba Health (241:HK) PT Raised to HK$4.60 at BofA SecuritiesBofA Securities analyst Miranda Zhuang raised the price target on Alibaba Health (241:HK) to HK$4.60 (from HK$4.50) while maintaining a Buy rating.
HSBC
HK$4.2
Buy
-0.94%
Downside
Reiterated
09/25/24
HSBC Reiterates Buy Rating on Alibaba Health (241:HK)HSBC analyst Charlene Liu reiterated a Buy rating and HK$4.20 price target on Alibaba Health (241:HK).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
HK$8.5
Buy
100.47%
Upside
Reiterated
07/04/25
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (NASDAQ: HRMY) and Alibaba Health Information Technology (Other OTC: ALBHF)
Macquarie Analyst forecast on HK:0241
Ellie JiangMacquarie
Macquarie
HK$3.4
Sell
-19.81%
Downside
Reiterated
06/24/25
Alibaba Health Information Technology (ALBHF) Receives a Sell from Macquarie
J.P. Morgan Analyst forecast on HK:0241
Alex YaoJ.P. Morgan
J.P. Morgan
HK$6HK$5
Hold
17.92%
Upside
Reiterated
06/04/25
J.P. Morgan Keeps Their Hold Rating on Alibaba Health Information Technology (ALBHF)
Goldman Sachs Analyst forecast on HK:0241
Lincoln KongGoldman Sachs
Goldman Sachs
Hold
Reiterated
06/04/25
Alibaba Health Information Technology (ALBHF) Receives a Hold from Goldman Sachs
UOB Kay Hian Analyst forecast on HK:0241
Unknown AnalystUOB Kay Hian
Not Ranked
UOB Kay Hian
HK$7HK$6.2
Buy
46.23%
Upside
Reiterated
05/21/25
CLSA
HK$4.5HK$4.8
Buy
13.21%
Upside
Reiterated
11/15/24
Alibaba Health (241:HK) PT Raised to HK$4.80 at CLSACLSA analyst Wenting Yu raised the price target on Alibaba Health (241:HK) to HK$4.80 (from HK$4.50) while maintaining a Outperform (2) rating.
Morgan Stanley Analyst forecast on HK:0241
Sean Wu CFAMorgan Stanley
Morgan Stanley
HK$5
Buy
17.92%
Upside
Reiterated
11/15/24
Positive Revenue and Profit Growth Drive 24% Upside Potential for Alibaba Health Information Technology
Jefferies Analyst forecast on HK:0241
Unknown AnalystJefferies
Not Ranked
Jefferies
HK$6
Buy
41.51%
Upside
Reiterated
10/25/24
Bank of America Securities Analyst forecast on HK:0241
Miranda ZhuangBank of America Securities
Bank of America Securities
HK$4.5HK$4.6
Buy
8.49%
Upside
Reiterated
10/16/24
Alibaba Health (241:HK) PT Raised to HK$4.60 at BofA SecuritiesBofA Securities analyst Miranda Zhuang raised the price target on Alibaba Health (241:HK) to HK$4.60 (from HK$4.50) while maintaining a Buy rating.
HSBC
HK$4.2
Buy
-0.94%
Downside
Reiterated
09/25/24
HSBC Reiterates Buy Rating on Alibaba Health (241:HK)HSBC analyst Charlene Liu reiterated a Buy rating and HK$4.20 price target on Alibaba Health (241:HK).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alibaba Health Information Technology

1 Month
xxx
Success Rate
3/4 ratings generated profit
75%
Average Return
+6.20%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +6.20% per trade.
3 Months
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
+21.50%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +21.50% per trade.
1 Year
Success Rate
2/2 ratings generated profit
100%
Average Return
+4.90%
reiterated a buy rating 8 months ago
Copying Wenting Yu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +4.90% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
100%
Average Return
+12.93%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +12.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0241 Analyst Recommendation Trends

Rating
Nov 24
Dec 24
May 25
Jun 25
Jul 25
Strong Buy
6
4
3
1
2
Buy
0
0
0
0
0
Hold
1
1
1
2
2
Sell
2
3
2
2
1
Strong Sell
0
0
0
0
0
total
9
8
6
5
5
In the current month, 0241 has received 2 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. 0241 average Analyst price target in the past 3 months is 5.81.
Each month's total comprises the sum of three months' worth of ratings.

0241 Financial Forecast

0241 Earnings Forecast

Next quarter’s earnings estimate for 0241 is HK$0.09 with a range of HK$0.09 to HK$0.09. The previous quarter’s EPS was HK$0.07. 0241 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.
Next quarter’s earnings estimate for 0241 is HK$0.09 with a range of HK$0.09 to HK$0.09. The previous quarter’s EPS was HK$0.07. 0241 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.

0241 Sales Forecast

Next quarter’s sales forecast for 0241 is HK$17.55B with a range of HK$17.44B to HK$17.66B. The previous quarter’s sales results were HK$17.55B. 0241 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.
Next quarter’s sales forecast for 0241 is HK$17.55B with a range of HK$17.44B to HK$17.66B. The previous quarter’s sales results were HK$17.55B. 0241 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.

0241 Stock Forecast FAQ

What is HK:0241’s average 12-month price target, according to analysts?
Based on analyst ratings, Alibaba Health Information Technology Ltd.’s 12-month average price target is 5.81.
    What is HK:0241’s upside potential, based on the analysts’ average price target?
    Alibaba Health Information Technology Ltd. has 37.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Alibaba Health Information Technology Ltd. a Buy, Sell or Hold?
          Alibaba Health Information Technology Ltd. has a consensus rating of Hold, which is based on 2 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Alibaba Health Information Technology Ltd.’s share price target?
            The average share price target for Alibaba Health Information Technology Ltd. is 5.81. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$8.50 ,and the lowest forecast is HK$3.40. The average share price target represents 37.00% Increase from the current price of HK$4.24.
              What do analysts say about Alibaba Health Information Technology Ltd.?
              Alibaba Health Information Technology Ltd.’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Alibaba Health Information Technology Ltd.?
                To buy shares of HK:0241, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis